AXL and metabolic dysfunction-associated steatohepatitis: In a mouse model for non-alcoholic steatohepatitis (NASH) it was shown that AXL signalling in primary fibroblasts, hepatocytes and liver macrophages promoted fibrosis, while GAS6 or MERTK activation protected primary hepatocytes against lipid toxicity, and the AXL inhibitor bemcentinib diminished liver inflammation and fibrosis in mice (Tutusaus et al., 2020).